Latest Alcohols Stories
New Study Should Not Impact Dietary Habits PARK RIDGE, Ill., April 25, 2013 /PRNewswire/ -- "Cardiovascular disease is a complex and individualized condition. While it is important to understand the relationship between the nutrients found in foods we eat and how our gut processes them, this singular study does not change the decades of research supporting the important role eggs play in a healthy diet. In fact, the media has misinterpreted the research and the authors'...
MIAMI, April 22, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma today announced its intent to divest its strategic issued patent for the detection of opioid abuse (US 7,214,385 "Pharmaceutical Formulation Containing Dye"). This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opioid drugs by visually demonstrating their misuse and abuse. For example, where a patient abuses a drug like oxycodone through nasal...
DALLAS, April 22, 2013 /PRNewswire/ -- The report "N-Butanol Market By Applications (Butyl Acrylate, Butyl Acetate, Glycol Ethers, and Others) & Geography-Global Trends & Forecasts to 2018" defines and segments the global n-butanol market with analysis and forecasting of the global demand and revenue for n-butanol. Browse 70 market data tables 34 figures 223 pages and an in-depth Table of Content on "N-Butanol Market"...
Baylor College of Medicine researchers will lead a three-year, $4.2 million study funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to determine whether drugs called beta blockers can ease airway narrowing in patients with asthma and examine potential mechanisms. Researchers from Duke University in Durham, North Carolina, and Washington University in St. Louis, Missouri, also will participate. "Previously, beta...
Recent U.S. FDA Approval of NDA Clears the Way for Commercialization MADISON, N.J. and TIGARD, Ore., April 19, 2013 /PRNewswire/ -- Bausch + Lomb, the global eye health company, and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month. "This agreement with Paragon demonstrates Bausch + Lomb's commitment to...
FLEMINGTON, N.J., April 18, 2013 /PRNewswire/ -- Neura Therapeutik announced today that they will be accelerating the development of their abuse-deterrent brand and generic extended-release opioids. This is in response to the Food and Drug Administration's recent announcement that they will not approve any generic to the original version of OxyContin® extended release oxycodone. The currently marketed version of OxyContin® possesses abuse-deterrent properties which the original...
Lawrence LeBlond for redOrbit.com - Your Universe Online Purdue Pharma’s OxyContin, a name-branded narcotic pain killer using the oxycodone formula, has long been a source of abuse for addicts. In a move to reduce that risk of abuse, Purdue in 2010 developed reformulated OxyContin tablets that would make it difficult for abusers to get a high off the drug. But as the patent was set to expire this week on the original OxyContin formula, addicts everywhere could soon have a new avenue...
-Oxycodone DETERx® resistant to tampering via chewing and crushing CANTON, Mass., April 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced top-line results from its recently completed Phase I clinical trial for Oxycodone DETERx®, its extended-release, abuse-deterrent, multi-particulate product in a capsule form. The product utilizes Collegium's DETERx®...
Company Targets Second Quarter of 2014 to File NDA As Development Activities Accelerate NORTH LIBERTY, Iowa, April 16, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has completed tablet manufacturing activities as part of the clinical and commercial development program for KP201. The manufactured tablets are a fixed-dose combination of KemPharm's...
Company Shows Robust Platform and Ability to Reproduce Pilot Scale Metrics MOUNTAIN VIEW, Calif., April 16, 2013 /PRNewswire/ -- Cobalt Technologies ("Cobalt"), a leading developer of next generation bio-based chemicals, today announced the successful completion of a production campaign of n-butanol at a fermentation scale greater than 100,000 liters. The performance demonstrates scalability by replicating the performance previously obtained at both the 10 liter bench scale and the 4,000...
